aidsmap news story
Targeted deployment of twice-yearly lenacapavir for pregnant and breastfeeding women without HIV in high-incidence districts in sub-Saharan Africa could substantially reduce vertical transmission at a fraction of the cost of universal rollout, according to a modelling study published in the Journal of the International AIDS Society. But the authors say lenacapavir should be seen as complementary to, not a substitute for, strengthening existing programmes to prevent vertical transmission.
Anna Yakusik of UNAIDS and colleagues carried out the modelling study, evaluating the cost-effectiveness of scaling up lenacapavir among pregnant and breastfeeding women without HIV across sub-Saharan Africa. They found that targeted deployment in high-incidence districts could reduce both maternal and paediatric HIV acquisitions, at a net cost of US$8,500 per acquisition averted, compared to US$85,000 under universal rollout.
Read the full news story here.
Source : aidsmap
Related HIV and Co-Infections News
-
IAVI: New Phase 1 trial launches to evaluate IAVI-developed HIV broadly neutralizing antibody
-
Liverpool School of Tropical Medicine: Researchers call for increased screening for parasitic disease linked to HIV and cervical cancer risk
-
HIV i-Base: Updated US paediatric HIV guidelines include dolutegravir from birth
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.